Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
J Nucl Med
.
2021 Dec;62(Suppl 3):23S-35S.
doi: 10.2967/jnumed.121.262751.
Authors
Richard L Wahl
1
,
George Sgouros
2
,
Amir Iravani
3
,
Heather Jacene
4
,
Daniel Pryma
5
,
Babak Saboury
6
,
Jacek Capala
6
,
Stephen A Graves
7
Affiliations
1
Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri rwahl@wustl.edu.
2
Department of Radiology, Johns Hopkins University, Baltimore, Maryland.
3
Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri.
4
Dana-Farber Cancer Institute, Boston, Massachusetts.
5
Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
6
National Institutes of Health, Bethesda, Maryland.
7
University of Iowa, Iowa City, Iowa.
PMID:
34857619
DOI:
10.2967/jnumed.121.262751
No abstract available
MeSH terms
Radiopharmaceuticals*
Substances
Radiopharmaceuticals